Trastuzumab is a humanized monoclonal antibody with antiangiogenic potential utilized for treating breast cancer in patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) [95,96]. Here, ERBB2 is linked to breast carcinoma.